Efficacy, Safety, and Tolerability of PF-06649751 in Parkinson’s Disease Patients at Early Stage of the Disease

A 15-Week, Phase 2, Double-Blind, Randomized, Placebo-Controlled, Flexible Dose Study to Investigate the
Efficacy, Safety and Tolerability of PF-06649751 in Subjects With Early Stage Parkinson’s Disease

Category & Conditions:
Neurological Diseases and Conditions
Medicine:
PF-06649751
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
B7601011
Open Plain Language Summary Result:Click here